Joris van de Haar
6PUBLICATIONS
54CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia
|Apr 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek
|Mar 06, 2024
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Yara L Verschoor, Joris van de Haar, José G van den Berg
|Feb 01, 2024
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.Joris van de Haar, Joanne M Mankor, Karlijn Hummelink
|Jan 08, 2024
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Yara L Verschoor, Joris van de Haar, José G van den Berg
|Oct 11, 2019
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.Salo N Ooft, Fleur Weeber, Krijn K Dijkstra
Pageof 1
Frequent Collaborators
6 joint publications
Emile E Voest
4 joint publications
Myriam Chalabi
3 joint publications
Lodewyk F A Wessels
3 joint publications
Monique van Leerdam
2 joint publications
Sara Balduzzi
2 joint publications
John B A G Haanen
2 joint publications
Erik Spickard
2 joint publications
Jolanda M van Dieren
2 joint publications
Noel F C C de Miranda
2 joint publications
Yara L Verschoor
